Otros idiomas Pacira BioSciences, Inc.

Acciones

PCRX

US6951271005

Farmacéuticos

Mercado cerrado - Nasdaq Otros sitios de cotización 22:00:00 08/12/2025			Variación 5 días	Varia. 1 de enero.
24,42 ^USD	+1,79 %		+3,04 %	+29,62 %

03/12	Pacira Biosciences Informa Sobre Concesiones de Incentivos Según la Norma Nasdaq	RE
02/12	Pacira: Iovera Supera a la Ablación por Radiofrecuencia en Dolor Lumbar Crónico	MT

Otros idiomas

Pacira Biosciences reports inducement grants under Nasdaq Listing Rule	03/12
Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	03/12
Pacira Says Iovera Outperformed Radiofrequency Ablation in Chronic Low Back Pain	02/12
Pacira BioSciences , Inc. Announces Results from 12-Month Pilot Study Demonstrating Favorable Safety and Significant Improvements in Pain Withioveradeg Compared to Radiofrequency Ablation in Chronic Low Back Pain	02/12
Pacira BioSciences Announces Results From 12-Month Pilot Study Demonstrating Favorable Safety and Significant Improvements in Pain With iovera° Compared to Radiofrequency Ablation in Chronic Low Back Pain	02/12
Pacira BioSciences Announces Results From 12-Month Pilot Study Demonstrating Favorable Safety and Significant Improvements in Pain With iovera° Compared to Radiofrequency Ablation in Chronic Low Back Pain	02/12
Pacira BioSciences Sues WhiteOak and Qilu Over EXPAREL Patents	26/11
Pacira BioSciences files Exparel patent infringement lawsuits against the WhiteOak Group and Qilu Pharmaceutical	26/11
Pacira BioSciences Files EXPAREL® Patent Infringement Lawsuits Against The WhiteOak Group and Qilu Pharmaceutical	26/11
Pacira Biosciences Insider Sold Shares Worth $266,405, According to a Recent SEC Filing	13/11
Pacira BioSciences to Participate in Fireside Chat at Two Upcoming Healthcare Conferences	11/11
Pacira BioSciences to Participate in Fireside Chat at Two Upcoming Healthcare Conferences	11/11
Doma Perpetual urges Pacira Biosciences to immediately explore sale of the business	11/11
DOMA Perpetual Sends Letter Calling for the Board of Directors of Pacira BioSciences, Inc. to Immediately Explore a Sale of the Business	11/11
DOMA Perpetual Sends Letter Calling Pacira BioSciences to Immediately Explore a Sale of the Business	11/11
Pacira BioSciences : PCRX 3Q25 Earnings Presentation FINAL	06/11
Pacira: Q3 Earnings Snapshot	06/11
Earnings Flash (PCRX) Pacira BioSciences, Inc. Posts Q3 Adjusted EPS $0.70 per Share, vs. FactSet Est of $0.65	06/11
Earnings Flash (PCRX) Pacira BioSciences, Inc. Reports Q3 Revenue $179.5M, vs. FactSet Est of $182.5M	06/11
Pacira Biosciences Q3 revenue misses estimates	06/11
Tranche Update on Pacira BioSciences, Inc.'s Equity Buyback Plan announced on May 8, 2025.	06/11
Pacira BioSciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025	06/11
Pacira BioSciences Reports Third Quarter 2025 Financial Results; Increases Full-year Gross Margin Guidance	06/11
Pacira BioSciences, Inc. Updates Earnings Guidance for the Year 2025	06/11
Pacira Biosciences Concludes Patient Enrollment in Part A of Phase 2 Study Evaluating Safety and Efficacy of PCRX-201 for the Treatment of Osteoarthritis of the Knee	05/11

No hay resultados para esta búsqueda

Todas Recomendaciones analistas Eventos destacados Insiders Transcripciones Comunicados Publs. oficiales Otros idiomas Ideas de trading Artículos de MarketScreener Estrategias MarketScreener

Otros idiomas Pacira BioSciences, Inc.

Acciones

PCRX

US6951271005

Farmacéuticos

Otros idiomas

Filtros